| | View this message online 
Hello manoj kumar valluru, New Feature - By popular demand, we've added a Send-to-a-Friend feature (BETA) so you can easily share our newsletters with your friends and colleagues. Just click the big 'Send to a Friend' button at the end of each newsletter. Last week an interesting paper was published describing how serum starvation of mesenchymal stem cells increases IGF-1 production by up to 200-fold. This may be an easy method of potentiating therapeutic effects of MSC in existing experimental scenarios. Perhaps more exciting was that the process of starvation was associated with epigenetic changes. 3 patents were issued of interest to our field. The first one, #7,455,962, teaches how to isolate hemangioblasts by selection for a CD34-like molecule called podocalyxin-like protein 1 (PCLP-1). The second patent, #7,455,983, covers methods of screening cultures of embryonic stem cells for media that can maintain the embryonic stem cells in an undifferentiated state, while allowing for their propagation. This is one of the few "methods of screening" patents that we have come across. The third patent, #7,456,333, discloses a transgenic mouse model of chronic myeloid leukemia (CML). This mouse has the leukemia-causing bcr-abl oncogene expressed selectively in cells positive for the stem cell antigen (SCA-1). The model resembles human CML pathology. Too bad these sorts of patents cant be issued in Canada.
RMSC 2008 World Congress (2-4 December 2008)
The 3rd Annual Stem Cells World Congress (20-22 January 2009)
The Stem Cell Meeting (March 2009)
Thanks again for your help in supporting StemCellPatents.com.
We welcome your comments and suggestions! Tell us here.
Media Partnerships (NEW)
NEW -  (BETA) Now you can send our newsletters to your friends and colleagues using our quick and easy send-to-a-friend feature (BETA).
------------------------------------------------------------ To unsubscribe, click here. Delivered: Monday December 1st, 2008 @ 15:15:35 EST | |
